@article{f8f1c246e66e4b199edfad3a73ec43ae,
title = "Celebrating 20 years of the UK Dermatology Clinical Trials Network. Part 1: Developing and delivering high‐quality independent clinical trials",
abstract = "The UK Dermatology Clinical Trials Network (UK DCTN) was formed in 2002 with the aim of developing and supporting high-quality independent national clinical trials that address prioritized research questions for people with skin disease. Its philosophy is to democratize UK dermatological clinical research and to tackle important clinical questions that industry has no incentive to answer. The network also plays a key role in training and capacity development. Its membership of over 1000 individuals includes dermatology consultants, trainees, dermatology nurses, general practitioners, methodologists and patients. Its organizational structures are lean and include a co-ordinating team based at the Centre of Evidence-Based Dermatology in Nottingham, and an executive with independent members to ensure probity and business progression. A prioritization panel and steering group enable a pipeline of projects to be prioritized and refined for external funding from independent sources. The UK DCTN has supported and completed 12 national clinical trials, attracting investment of over £15 million into UK clinical dermatology research. Trials have covered a range of interventions from drugs such as doxycycline (BLISTER), silk clothing for eczema (CLOTHES) and surgical interventions for hidradenitis suppurativa (THESEUS). Trial results are published in prestigious journals and have global impact. Genuine partnership with patients and carers has been a strong feature of the network since its inception. The UK DCTN is proud of its first 20 years of collaborative work, and aims to remain at the forefront of independent dermatological health technology assessment, as well as expanding into areas including diagnostics, artificial intelligence, efficient studies and innovative designs.",
keywords = "Artificial Intelligence, Caregivers, Clinical Trials as Topic, Dermatology, Eczema, Humans, United Kingdom",
author = "{UK Dermatology Clinical Trials Network} and Williams, {Hywel C} and McPhee, {Margaret J} and Layfield, {Carron P}",
note = "Funding Information: The UK DCTN thanks the BAD for its sustained support over the last 20 years and all of the UK DCTN individual members including patients and those who serve on its committees (see Appendix) who give their time freely to support the network. The UK DCTN is a registered UK charity (number 1115745) and is subject to Charity Commission rules. The network infrastructure is funded by the BAD and the University of Nottingham, with contribution in kind and donations from its members. The network also receives some funding for continuing support and dissemination from successful applications. The network does not accept funding from the pharmaceutical industry or other for-profit organizations. Learning points The UK DCTN is a democratic network that strives to support high-quality clinical trials in dermatology. Patients are and always have been at the heart of the network. Clinical trial suggestions come from the network membership. Trial prioritization follows a process starting with an outline vignette that is heard by a steering group. The network directly supports the development of prioritized trial suggestions by means of surveys, expert critique and by directly funding feasibility studies. The output of UK DCTN has shown what is possible by working collaboratively across professional boundaries. The UK DCTN is a democratic network that strives to support high-quality clinical trials in dermatology. Patients are and always have been at the heart of the network. Clinical trial suggestions come from the network membership. Trial prioritization follows a process starting with an outline vignette that is heard by a steering group. The network directly supports the development of prioritized trial suggestions by means of surveys, expert critique and by directly funding feasibility studies. The output of UK DCTN has shown what is possible by working collaboratively across professional boundaries. Publisher Copyright: {\textcopyright} 2022 The Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.",
year = "2022",
month = jun,
day = "1",
doi = "10.1111/ced.15140",
language = "English",
volume = "47",
pages = "1048--1059",
journal = "Clinical and Experimental Dermatology ",
issn = "0307-6938",
publisher = "Oxford University Press",
number = "6",
}